Antibiotic Summary Flashcards
Fe/Ca/Mag/Al interference with bioavailability
flouroquinolones
tetracyclines
predominantly G+ drugs
vanco
dapto
rifampin
fidaxomicin
linezolid
penicillinases
penicillin
predominantly G- drugs
aztrenonam
ceftazidime
cipro
polymyxins
time dependent
TMP/SMZ
B-lactams
linezolid
exposure dependent
tigecycline
tetracyclines
polymyxins
rifampin
macrolides
vanco
clindamycin
myelosuppression
linezolid
bacteriodes coverage
aminopenicillins + inhibitors
extended spec penicillins + inhibitors
carbapenems
cefoxitin
clindamycin
metronidazole
moxifloxacin
tigecycline
seizures/CNS
imipenem
(B-lactams more broadly too)
flouroquinolones
flouroquinolones that don’t need renal dose adjustment
moxifloxacin
CNS penetration
3rd + 4th gen cephalosporins
meropenem
vanco
high C diff risk
clindamycin
flouroquinolones
very low Vd
aminoglycosides
dapto
nitrofurantoin
polymyxins
B-lactams that don’t need renal dose adjustment
ceftriaxone
penicillinases
pseudo coverage
extended spectrum penicillins
cefepime, ceftazidime
dori, mero, imi -penem
aztreonam
gentamicin, tobramycin, amikacin
levo, cipro -floxacin
polymyxins
G- as well as G+ synergy
aminoglycosides
atypicals coverage
(legionella, myco, chlyamydia)
macrolides
tetracyclines
flouroquinolones
MRSA coverage
vanco
dapto
linezolid
clindamycin
ceftaroline
tetracyclines
tigecycline
TMP/SMZ
myopathy
dapto
predominantly anero
metronidazole
G+ and anero
clindamycin
nephrotoxic
aminoglycosides
polymyxins
vanco
VRE coverage
linezolid
dapto
tigecycline (better than tetracyclines)
pulmonary fibrosis
nitrofurantoin
rash
TMP/SMZ
B-lactams
vanco (Red Man’s)
concentration dependent
aminoglycosides
quinolones
dapto
metronidazole